Defunct Company
Total Trials
7
As Lead Sponsor
As Collaborator
0
Total Enrollment
147
NCT02941523
Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours
Phase: Phase 1/2
Role: Lead Sponsor
Start: Mar 3, 2017
Completion: Jan 10, 2019
NCT03307629
Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer
Phase: Phase 1
Start: Nov 1, 2017
Completion: Sep 15, 2020
NCT03780465
A Study of Safety and Tolerability of NOX66 in Healthy Volunteers
Start: Mar 1, 2019
Completion: Mar 1, 2019
NCT04555213
A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19
Start: Sep 30, 2020
Completion: Aug 10, 2021
NCT04957290
A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Start: Oct 25, 2021
Completion: Jun 7, 2023
NCT05100628
A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma
Start: Feb 11, 2022
Completion: May 26, 2023
NCT07072611
Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants
Phase: Early Phase 1
Start: Jul 14, 2025
Completion: Mar 31, 2026